The epidemiology and microbiological characteristics of infections caused by Gram-negative bacteria in Qatar: national surveillance from the Study for Monitoring of Antimicrobial Resistance Trends (SMART): 2017 to 2019.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
04
04
2023
accepted:
26
06
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
The global Study of Monitoring Antimicrobial Resistance Trends (SMART) is a surveillance program for evaluation of antimicrobial resistance (AMR) in Gram-negative bacteria (GNB) from different regions including Gulf countries. To evaluate AMR in GNB from various clinical specimens including microbiological and genetic characteristics for existing and novel antimicrobials. A prospective study was conducted on clinical specimens from Hamad Medical Corporation, Qatar, between 2017 and 2019 according to the SMART protocol. Consecutive GNB from different sites were evaluated including lower respiratory, urinary tract, intrabdominal and bloodstream infections. Over the 3 years study period, 748 isolates were evaluated from the specified sites comprising 37 different GNB outlining four key pathogens: Surveillance of GNB from Qatar showed prevalence of key pathogens similar to other regions but demonstrated significant resistance patterns to existing and novel antimicrobials with different underlying resistance mechanisms.
Sections du résumé
Background
UNASSIGNED
The global Study of Monitoring Antimicrobial Resistance Trends (SMART) is a surveillance program for evaluation of antimicrobial resistance (AMR) in Gram-negative bacteria (GNB) from different regions including Gulf countries.
Objectives
UNASSIGNED
To evaluate AMR in GNB from various clinical specimens including microbiological and genetic characteristics for existing and novel antimicrobials.
Methods
UNASSIGNED
A prospective study was conducted on clinical specimens from Hamad Medical Corporation, Qatar, between 2017 and 2019 according to the SMART protocol. Consecutive GNB from different sites were evaluated including lower respiratory, urinary tract, intrabdominal and bloodstream infections.
Results
UNASSIGNED
Over the 3 years study period, 748 isolates were evaluated from the specified sites comprising 37 different GNB outlining four key pathogens:
Conclusions
UNASSIGNED
Surveillance of GNB from Qatar showed prevalence of key pathogens similar to other regions but demonstrated significant resistance patterns to existing and novel antimicrobials with different underlying resistance mechanisms.
Identifiants
pubmed: 37546546
doi: 10.1093/jacamr/dlad086
pii: dlad086
pmc: PMC10400155
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlad086Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Clin Microbiol Rev. 2013 Jul;26(3):361-80
pubmed: 23824364
J Antimicrob Chemother. 2019 Dec 1;74(12):3497-3504
pubmed: 31504587
Antibiotics (Basel). 2020 Apr 20;9(4):
pubmed: 32326058
Med Sci (Basel). 2017 Dec 21;6(1):
pubmed: 29267233
Eur J Clin Microbiol Infect Dis. 2021 Aug;40(8):1779-1785
pubmed: 33616788
Clin Infect Dis. 2002 Mar 1;34(5):634-40
pubmed: 11823954
World J Emerg Surg. 2021 Sep 25;16(1):49
pubmed: 34563232
Lancet Infect Dis. 2018 Mar;18(3):e99-e106
pubmed: 29102325
Curr Opin Microbiol. 2017 Oct;39:96-105
pubmed: 29154026
Antimicrob Agents Chemother. 2010 Jul;54(7):3043-6
pubmed: 20421398
J Chemother. 2017 Dec;29(sup1):2-9
pubmed: 29271736
Antibiotics (Basel). 2019 Apr 06;8(2):
pubmed: 30959901
J Infect Public Health. 2019 Jul - Aug;12(4):465-471
pubmed: 31060974
Curr Opin Crit Care. 2018 Oct;24(5):347-352
pubmed: 30063491
Antimicrob Resist Infect Control. 2020 Nov 1;9(1):170
pubmed: 33131487
Antimicrob Steward Healthc Epidemiol. 2022 Jun 20;2(1):e96
pubmed: 36483382
Front Microbiol. 2020 Nov 11;11:581711
pubmed: 33262745
Intensive Care Med. 2020 Feb;46(2):163-172
pubmed: 31701205
Clin Microbiol Infect. 2020 Feb;26(2):151-157
pubmed: 31712069
Clin Microbiol Infect. 2017 Oct;23(10):704-712
pubmed: 28893690
Front Microbiol. 2019 Aug 20;10:1823
pubmed: 31481937
Glob Health Med. 2019 Dec 31;1(2):61-64
pubmed: 33330756
Clin Microbiol Infect. 2014 Jan;20 Suppl 1:1-55
pubmed: 24329732
Antimicrob Resist Infect Control. 2016 Feb 09;5:4
pubmed: 26865975
Oman Med J. 2022 Sep 30;37(5):e422
pubmed: 36188876
Int J Antimicrob Agents. 2019 Dec;54(6):790-797
pubmed: 31284041
Clin Infect Dis. 2018 Apr 3;66(8):1290-1297
pubmed: 29165604
BMC Med. 2018 Jun 4;16(1):78
pubmed: 29860943
Pharmaceuticals (Basel). 2013 Nov 01;6(11):1335-46
pubmed: 24287460
Antibiotics (Basel). 2022 Jan 19;11(2):
pubmed: 35203733
Intensive Care Med. 2017 Oct;43(10):1464-1475
pubmed: 28733718
Antibiotics (Basel). 2021 Mar 11;10(3):
pubmed: 33799540
Front Microbiol. 2019 Aug 23;10:1941
pubmed: 31507558
J Chemother. 2015 Feb;27(2):67-73
pubmed: 24548089
Emerg Microbes Infect. 2022 Dec;11(1):811-814
pubmed: 35240944
Clin Microbiol Rev. 2020 Feb 26;33(2):
pubmed: 32102899
Clin Infect Dis. 2017 May 15;64(suppl_2):S51-S60
pubmed: 28475791
Diagn Microbiol Infect Dis. 2012 Aug;73(4):354-60
pubmed: 22656912
Travel Med Infect Dis. 2010 Nov;8(6):377-87
pubmed: 21074495
J Clin Med. 2020 Jan 19;9(1):
pubmed: 31963877
JAC Antimicrob Resist. 2020 Aug 07;2(3):dlaa050
pubmed: 34223010
Antimicrob Resist Infect Control. 2018 Apr 25;7:58
pubmed: 29713465
Clin Microbiol Rev. 2019 Aug 28;32(4):
pubmed: 31462403
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30559135
Open Forum Infect Dis. 2021 Jan 05;8(2):ofaa651
pubmed: 33598503
Int J Antimicrob Agents. 2012 Apr;39(4):283-94
pubmed: 22386741